

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 3-7, 9, 15, 17, 20, 30-31, 34-35, and 39 without prejudice or disclaimer.

Please amend pending claims 1, 14, and 38 as noted below.

1. (Currently amended) An isolated TgAMA-1 polypeptide molecule ~~comprising~~ consisting essentially of an antigenic fragment of the polypeptide sequence set forth as amino acids 23-456 of SEQ ID NO:1.

2. (Original) A fusion protein comprising the antigenic polypeptide of claim 1.

3-13. (Cancelled)

3 14. (Currently Amended) A ~~vaccine~~ composition comprising the isolated TgAMA-1 polypeptide of claim 1 and ~~an adjuvant~~.

a pharmaceutically acceptable carrier.

15-22. (Cancelled)

6 23. (Original) A TgAMA-1 binding polypeptide that selectively binds to the isolated TgAMA-1 polypeptide of claim 1.

7 24. (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding polypeptide is an antibody ~~or antigen-binding fragment of an antibody~~.

8 ~~25.~~ (Original) The TgAMA-1 binding polypeptide of claim 24, wherein the antibody ~~or~~
~~antigen-binding fragment~~ specifically binds to a region comprising about 12 or more cysteine
residues of the isolated polypeptide of claim 1.

9 ~~26.~~ (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding
polypeptide blocks entry of Toxoplasma parasite into a cell.

27-37. (Cancelled)

4 ~~38.~~ (Previously Presented) The ~~vaccine~~ composition of claim ³ ~~14~~, wherein the ~~vaccine~~
composition is a proteosome vaccine.

39. (Cancelled)

5 ~~40~~ The composition of claim ³ ~~14~~, wherein the
composition includes an adjuvant.